Group 1 - The North Exchange 50 index decreased by 2.16%, with a trading volume of 1503.29 billion, reflecting an 8% decrease week-on-week [12][17][27] - The new code switching pilot for six stocks will be launched after May Day, aimed at enhancing the recognition of the North Exchange and distinguishing it from the New Third Board [12][13][54] - The report emphasizes a cautious approach before the holiday and a non-pessimistic outlook afterward, suggesting a focus on technology sectors that have undergone sufficient adjustments [13][17][49] Group 2 - No new stocks were listed on the North Exchange this week, with a total of 265 companies currently trading [3][31] - The New Third Board saw nine new listings and 18 delistings, with no new financing plans and a completed financing of 0.50 billion [4][55] - The report highlights the performance of specific companies, with notable gains for Fangda New Materials and Zhongyu Technology, while companies like Minshida and Kangbiter faced significant declines [39][40][42] Group 3 - The average PE (TTM) for the North Exchange is 78.81 times, with a median of 47.08 times, indicating a higher valuation compared to other exchanges [24][26] - The report notes that the financing balance for margin trading on the North Exchange increased to 53.14 billion, reflecting a slight rise from the previous week [30][27] - Key announcements include the issuance of guidelines for share changes and updates to the listing rules by the Beijing Stock Exchange [49][51]

英杰电气(300820) 报告日期：2025 年 04 月 27 日 业绩短期承压，半导体射频电源迈向 5nm 先进制程 ——英杰电气点评报告 投资要点 ❑ 2024 年报&2025Q1 业绩：短期承压；期待半导体射频电源进展提速 证券研究报告 | 公司点评 | 其他电源设备Ⅱ 1）2024 年报：营收 17.8 亿元，同比增长 0.6%；归母净利润 3.2 亿元，同比下滑 25.2%。年 毛利率 38.5%，同比提升 1.3pct；净利率 18.8%，同比下降 5.5pct。 收入结构——光伏：8.7 亿元、同比下滑 10.3%，毛利率 28.5%、同比-2.4pct；半导体：3.5 亿元、同比增长 6.4%，毛利率 54%、同比+11.1pct；其他领域：5.5 亿元、同比增长 18.9%， 毛利率 44.6%、同比-2pct。 2）2025Q1 业绩：营收 3.3 亿元，同比下滑 13.3%；归母净利润 0.5 亿元，同比下滑 37%。毛 利率 37.8%，同比下降 4.2pct；净利率 15.8%，同比下降 6.6pct。 3）订单：截至 2025 年 Q1 末，合同负债达 11.8 亿元，同比下滑 ...

证券代码：002215 证券简称：诺 普 信 深圳诺普信作物科学股份有限公司投资者关系活动记录表 | 投资者关系活 | □特定对象调研 □分析师会议 | | --- | --- | | 动类别 | □媒体采访 ☑业绩说明会 | | | □路演活动 □新闻发布会 | | | □现场参观 □其他 | | 参与单位名称 及人员姓名 | 中信证券、汇添富基金、易方达基金、国泰海通、民生证券、长 盛基金、上海庐雍资产、上海华汯资产、兴业银行、磐厚动量、 | | | 民生加银基金、中信保诚资产、浙江伟星资产、宏利资产、国投 | | | 证券、上海观火投研、申万宏源、天风农业、大正投资、睿胜投 | | | 资、雷钧资产、东北证券、崇山资本、汇智源林私募基金、天弘 | | | 基金、人保资产、上海卓恒私募基金、新华基金、农银人寿保险、 | | | 工银安盛、凯丰投资、华能贵诚信托、深圳蓝焱资本、深圳宏鼎 | | | 财富、昆仑健康保险、西部利得基金、中原证券、华夏财富、开 | | | 源证券、长江证券、博闻投资、姜雷、范世强。 | | 时间 | 2025 年 4 月 24 日 20:45-21:45 | | 地点 | 线上电 ...

证券研究报告 | 公司点评 gszqdatemark 2025 04 27 年 月 日 中国化学（601117.SH） 当前时点如何看中国化学？ 估值处于历史底部，现金流情况优异，有息债务率极低，分红具备较大提升空间。公司 当前 PB 为 0.75 倍，处于近 10 年的 6.2%分位，具备较强安全边际。公司 2024Q3 末 有息债务率仅为 6.3%（8 大建筑央企中最低），在手现金类资产 397 亿元，减去有息 债务后为 256 亿元（公司当前市值为 453 亿元），是 8 大建筑央企中唯一在手现金大于 有息负债的公司。公司自上市以来每年经营性现金流净额均为正，且近五年（2019-2023 年）经营性现金流与投资性现金流净额之和为 139 亿元（8 大建筑央企仅有中国化学与 中国中冶为正）。公司现金流及资产负债表情况实际与中钢国际、中材国际等公司特征 类似（自由现金流为正、有息债务率低、在手现金大于有息债务），相较于两家公司平 均 43%的分红率，未来公司分红率（目前 20%）具备较大潜在提升空间。 己二腈项目运行顺利，受益进口替代加速及原材料价格下行，盈利有望明显提升。公司 己二腈项目整体进展顺利，负荷 ...

传统的进口替代战略依靠关税或者非关税壁垒，使本国企业在受保护的环境中成长，比如美国政府为了 促进制造业回流正在实施的关税战。 日前，美国著名智库兰德公司中国研究中心代理副主任杰拉德·迪皮波和欧洲研究主管弗朗西斯卡·吉雷 蒂等共同发表评论文章称，美国政府正通过征收关税刺激制造业回流，而中国经历了人类历史上最大规 模的工业化，一跃成为全球最大的制造业和出口国家。在美国试图重振制造业之际，中国的经验或能为 美国带来益处。 中国工业化不依赖关税 评论这样总结中国的产业政策：提升价值链，引领未来技术，赢得全球市场份额，实现自力更生，同时 着眼国家安全。 中国制造业的发展重点是自动化。随着中国企业采用人工智能、机器人和先进制造技术，许多工厂被设 计为无人自动运转工厂。中国的机器人密度（每万名员工安装的工业机器人数量）在4年内翻了一番， 截至2023年，中国机器人密度已经超过美国。 政府重视支持研发创新 评论写道，中国的研发支出大幅增加，包括增加对技术研发的税收优惠，并大力拓展基础研究。目前， 中国大部分研发支出由企业承担，但政府研发支出增长迅速。中国的科技预算已经连续十年超过GDP的 0.8%。按购买力平价计算，中国的研 ...

科拜尔主要从事功能性改性塑料和色母料的研发、生产与销售，产品主要应用于家用电器、日用消费品、汽车 零部件等领域。经过十余年行业深耕，公司已与四川长虹、美的集团、TCL、惠而浦、海信集团等家电龙头企 业建立了稳定的合作关系。 4月16日，合肥科拜尔新材料股份有限公司（股票代码：920066，简称：科拜尔）发布上市后首份年度业绩报 告。报告显示，2024年公司实现营业收入45,376.30万元，较上年同期增长16.73%；归母净利润4,852.12万元，同 比增长7.25%，呈现出营收利润双增长的良性发展态势，公司盈利能力持续增强。 家电行业景气度攀升，两大主营业务深度受益 料ESCR（耐环境应力开裂）保持率较HIPS材料提升超20%，不仅攻克了困扰行业的"胆裂"难题，更达到国际先 进水平，打破了跨国企业对冰箱内胆材料的长期垄断，实现了关键材料的进口替代与供应链自主可控。 技术突破离不开持续的研发投入。年报显示，2024年，科拜尔研发费用达1,746.57万元，与2023年基本持平，研 发投入强度保持在3.85%的行业较高水平。持续的研发投入结出硕果，公司当年新增授权发明专利3项，并以第 一起草单位主导发布团体标 ...

Core Viewpoint - Tonghe Pharmaceutical reported a revenue of 759 million yuan for 2024, a year-on-year increase of 5.1%, and a net profit attributable to shareholders of 107 million yuan, up 0.6% [1] Group 1: Company Performance - The company's operating cash flow net amount reached 285 million yuan, growing by 74.2% [1] - The company focuses on the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates, with a leading production capacity and product quality in China [2][3] - The company has over 600 various types of enamel and metal reaction kettles, with a total volume exceeding 3 million liters [2] Group 2: Market Outlook - The global active pharmaceutical ingredient (API) market is expected to see significant growth, with approximately 300 billion USD worth of original drugs set to lose patent protection from 2019 to 2026, leading to a potential API market increase of nearly 200 billion yuan [2] - China is a major global producer and supplier of APIs, and the implementation of centralized procurement policies is expected to enhance the concentration of pharmaceutical companies and increase the space for import substitution [3] Group 3: Strategic Focus - The company emphasizes focusing on its core business, avoiding diversification, and aims to strengthen its position in the chemical pharmaceutical industry [4] - The average R&D investment over the past three years accounted for 8.34% of sales, with increased focus on various therapeutic areas [4] - The company plans to enhance domestic market development while maintaining a strong export focus, aiming for simultaneous sales in both domestic and international markets [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：688607 公司简称：康众医疗 第一节 重要提示 公司2024年年度利润分配方案为： 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到www.sse.com.cn网站仔细阅读年度报告全文。 2、重大风险提示 公司已在本报告中详细阐述经营过程中可能存在的相关风险，敬请查阅"第三节 管理层讨论与分 析"之"四、风险因素"中有关风险的说明。 3、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 4、公司全体董事出席董事会会议。 5、立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 6、公司上市时未盈利且尚未实现盈利 □是 √否 7、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 1.2公司存托凭证简况 公司拟向全体股东每10股派发现金红利人民币0.61元（含税）。根据《上市公司股份回购规则》《上海 证券交易所上市公司自律监管指引第7号一一回购股份》等有关规定，上 ...

Core Insights - Bid Medicine (688073.SH) reported a revenue of 1.102 billion yuan for 2024, a year-on-year increase of 0.93%, and a net profit of 117 million yuan, up 7.17% year-on-year [1] - In Q1 2025, the company continued its steady performance with a revenue of 296 million yuan, and a net profit growth of 17.71% year-on-year, with adjusted net profit excluding share-based payments increasing by 43.29% [1] - The company is positioned as a leading player in the global molecular building blocks industry, focusing on digital upgrades and process optimization to enhance management efficiency and profitability [1][2] Business Performance - The molecular building blocks segment generated 936 million yuan in revenue, maintaining stable market share, while the scientific reagents segment saw a 13.35% year-on-year growth, reaching 166 million yuan [3] - The company has nearly 130,000 types of products, including 117,000 types of molecular building blocks, significantly exceeding industry averages [3] - R&D achievements have increased, with 41 patent applications, a 156% year-on-year rise, and a 56% increase in delivered orders [3] Market Trends - The global biopharmaceutical investment landscape has improved, with the CXO industry entering an upward cycle due to supply-demand balance [2] - The ongoing U.S.-China pharmaceutical tariff disputes have shifted towards "precise technology blockades," accelerating the trend of import substitution [2] - The global market for molecular building blocks is projected to reach 54.6 billion USD by 2026, presenting significant growth opportunities for the company [3] Global Strategy - The company achieved overseas revenue of 616 million yuan in 2024, a 10.58% increase, accounting for approximately 55.9% of total revenue [4] - Bid Medicine has established regional centers in the U.S., Germany, and India to enhance local service efficiency and customer response [4] - The company aims to strengthen its global presence through localized teams and resource integration, aspiring to become a leading supplier in the molecular building blocks sector [4][5]

Core Viewpoint - The company focuses on the research, production, and sales of hydraulic pipeline systems, with a strong emphasis on providing clean, safe, and leak-free solutions to various industries, including construction machinery and mining [5][7]. Company Overview - The company primarily engages in the development, production, and sales of hydraulic pipeline systems, including hard pipe assemblies, soft pipe assemblies, pipe joints, and oil tanks [5]. - The company has established a competitive advantage by providing close service and comprehensive solutions to clients, accumulating quality customer resources over the years [5]. Business Performance - In 2024, the company achieved total operating revenue of 468.54 million yuan, an increase of 49.06 million yuan, representing a year-on-year growth of 11.69% [7]. - The net profit attributable to shareholders was 72.40 million yuan, a decrease of 5.66 million yuan, reflecting a year-on-year decline of 7.25% [7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 64.79 million yuan, a slight increase of 0.15 million yuan, indicating a year-on-year growth of 0.23% [7]. Market Position and Industry Development - The hydraulic industry in China has been developing rapidly, with a significant market size and a gradual shift towards domestic product substitution for high-end markets previously dominated by foreign companies [9][12]. - The company's products are crucial components in hydraulic systems, accounting for approximately 15% of the system's value, and the company has achieved a leading position in the domestic hydraulic hard pipe assembly segment [9][10]. Key Drivers of Performance - The main application markets for the company's products are the construction machinery market and the mining machinery aftermarket, with construction machinery accounting for 56.7% of the company's revenue [10]. - The domestic excavator sales in 2024 saw a year-on-year increase of 3.13%, indicating a recovery in the construction machinery sector [7][10]. - The mining machinery aftermarket is characterized by stable demand, driven by the maintenance needs of existing equipment, with coal and non-ferrous metal mining showing growth in production [10][12]. Operational Model - The company adopts a close-service business model, primarily supplying products to major manufacturers in the construction machinery sector and providing services to the mining machinery aftermarket [13]. - The procurement strategy includes centralized purchasing for major raw materials to reduce costs, while production is based on customer orders [13][14].